OPN 305

Drug Profile

OPN 305

Alternative Names: Anti-TLR2 monoclonal antibody - Opsona Therapeutics; Anti-Toll-like receptor 2 monoclonal antibody - Opsona Therapeutics; OPN-305

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Opsona Therapeutics
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Toll like receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function; Myelodysplastic syndromes
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Delayed graft function
  • Phase I/II Myelodysplastic syndromes
  • No development reported Autoimmune disorders; Inflammation

Most Recent Events

  • 20 Dec 2016 Preliminary efficacy, pharmacokinetics and safety data from a phase I/II trial in Myelodysplastic syndrome presented at the 58th Annual Meeting of the American Society of Hematology (ASH-2016)
  • 25 Oct 2016 OPN 305 receives Orphan Drug status for Myelodysplastic syndromes in USA
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Ireland (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top